| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article
- Language: English
- [J Endocrinol Invest] 2021 Jan; Vol. 44 (1), pp. 75-81. <i>Date of Electronic Publication: </i>2020 Apr 27.
- MeSH Terms: Biomarkers / *blood ; Blood Glucose / *analysis ; Diabetes Mellitus, Type 2 / *diagnosis ; Prediabetic State / *diagnosis ; Aged ; Diabetes Mellitus, Type 2 / blood ; Diabetes Mellitus, Type 2 / epidemiology ; Female ; Follow-Up Studies ; Glucose Tolerance Test ; Glycated Hemoglobin / analysis ; Humans ; Italy / epidemiology ; Male ; Middle Aged ; Prediabetic State / blood ; Prediabetic State / epidemiology ; Prognosis ; Risk Factors ; Surveys and Questionnaires
- References: WHO (2013) World health statistics. World Health Organization, Geneva, Switzerland. ; International Diabetes Federation (2017) IDF diabetes atlas 8th edition. International Diabetes Federation. ; United Nations (2007) Resolution adopted by the General Assembly on 20 December 2006. World Diabetes Day. Ares 61/225. ; Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE (2002) The rising prevalence of diabetes and impaired glucose tolerance: the Australian diabetes. Obes Lifestyle Study Diabetes Care 25:829–834. ; Glümer C, Jørgensen T, Borch-Johnsen K, Inter99 study (2003) Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Care 26:2335–2340. (PMID: 10.2337/diacare.26.8.2335) ; Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW (2006) Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care 29:1263–1268. (PMID: 10.2337/dc06-0062) ; Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B (2018) IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138:271–281. (PMID: 10.1016/j.diabres.2018.02.023) ; Harris MI (1993) Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 16:642–652. (PMID: 10.2337/diacare.16.4.642) ; Porta M, Curletto G, Cipullo D, Rigault de la Longrais R, Trento M, Passera P, Taulaigo AV, Di Miceli S, Cenci A, Dalmasso P, Cavallo F (2014) Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence. Diabetes Care 37:1668–1674. (PMID: 10.2337/dc13-2101) ; Zheng Y, Ley SH, Hu FB (2018) Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 14:88–98. (PMID: 10.1038/nrendo.2017.151) ; UKPDS Group (1990) UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and its association with different clinical and biochemical risk factors. Diabetes Res 13:1–1111. ; Spijkerman AM, Dekker JM, Nijpels G, Adriaanse MC, Kostense PJ, Ruwaard D, Stehouwer CD, Bouter LM, Heine RJ (2003) Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study. Diabetes Care 26:2604–2608. (PMID: 10.2337/diacare.26.9.2604) ; Spijkerman AM, Henry RM, Dekker JM, Nijpels G, Kostense PJ, Kors JA, Ruwaard D, Stehouwer CD, Bouter LM, Heine RJ (2004) Prevalence of macrovascular disease amongst type 2 diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn Screening Study. J Intern Med 256:429–436. (PMID: 10.1111/j.1365-2796.2004.01395.x) ; Chatterjee R, Narayan KM, Lipscomb J, Jackson SL, Long Q, Zhu M, Phillips LS (2013) Screening for diabetes and prediabetes should be cost-saving in patients at high risk. Diabetes Care 36:1981–1987. (PMID: 10.2337/dc12-1752) ; Christensen JO, Sandbaek A, Lauritzen T, Borch-Johnsen K (2004) Population-based stepwise screening for unrecognised type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia 47:1566–1573. (PMID: 10.1007/s00125-004-1496-2) ; Sargeant LA, Simmons RK, Barling RS, Butler R, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ (2010) Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. Diabetic Med 27:995–1003. (PMID: 10.1111/j.1464-5491.2010.03056.x) ; Hosler AS, Berberian EL, Spence MM, Hoffman DP (2005) Outcome and cost of a statewide diabetes screening and awareness initiative in New York. J Publ Health Manag Pract 11:59–64. (PMID: 10.1097/00124784-200501000-00010) ; Shono A, Kondo M, Hoshi SL, Okubo R, Yahagi N (2018) Cost-effectiveness of a new opportunistic screening strategy for walk-in fingertip HbA1c testing at community pharmacies in Japan. Diabetes Care 41:1218–1226. (PMID: 10.2337/dc17-1307) ; Simmons RK, Rahman M, Jakes RW, Yuyun MF, Niggebrugge AR, Hennings SH, Williams DRR, Wareham NJ, Griffin SJ (2011) Effect of population screening for type 2 diabetes on mortality: long-term follow-up of the Ely cohort. Diabetologia 54:312–319. (PMID: 10.1007/s00125-010-1949-8) ; Herman WH, Ye W, Griffin SJ, Simmons RK, Davies MJ, Khunti K, Rutten GE, Sandbaek A, Lauritzen T, Borch-Johnsen K, Brown MB, Wareham NJ (2015) Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: a simulation of the results of the Anglo-Danish-Dutch study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION-Europe). Diabetes Care 38:1449–1455. (PMID: 10.2337/dc14-2459) ; Simmons RK, Griffin SJ, Lauritzen T, Sandbaek A (2017) Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 1,912,392 individuals diagnosed with diabetes in Denmark between 2001 and 2009. Diabetologia 60:2192–2199. (PMID: 10.1007/s00125-017-4299-y) ; Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, Davies MJ, Khunti K (2008) Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 336:1180–1185. (PMID: 10.1136/bmj.39545.585289.25) ; Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M (2004) Population-based incidence rates and risk factors for type 2 diabetes in Caucasians: the Bruneck study. Diabetes 53:1782–1789. (PMID: 10.2337/diabetes.53.7.1782) ; Bonora E, Kiechl S, Oberhollenzer F, Egger G, Bonadonna RC, Muggeo M (2000) Impaired glucose tolerance, type 2 diabetes mellitus and carotid atherosclerosis. Prospective results from the Bruneck study. Diabetologia 43:156–164. (PMID: 10.1007/s001250050024) ; Emerging Risk Factors Collaborators, Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, Kaptoge S, Kondapally Seshasai SR, Thompson A, Sarwar N, Willeit P, Ridker PM, Barr EL, Khaw KT, Psaty BM, Brenner H, Balkau B, Dekker JM, Lawlor DA, Daimon M, Willeit J, Njølstad I, Nissinen A, Brunner EJ, Kuller LH, Price JF, Sundström J, Knuiman MW, Feskens EJ, Verschuren WM, Wald N, Bakker SJ, Whincup PH, Ford I, Goldbourt U, Gómez-de-la-Cámara A, Gallacher J, Simons LA, Rosengren A, Sutherland SE, Björkelund C, Blazer DG, Wassertheil-Smoller S, Onat A, Marín Ibañez A, Casiglia E, Jukema JW, Simpson LM, Giampaoli S, Nordestgaard BG, Selmer R, Wennberg P, Kauhanen J, Salonen JT, Dankner R, Barrett-Connor E, Kavousi M, Gudnason V, Evans D, Wallace RB, Cushman M, D'Agostino RB Sr, Umans JG, Kiyohara Y, Nakagawa H, Sato S, Gillum RF, Folsom AR, van der Schouw YT, Moons KG, Griffin SJ, Sattar N, Wareham NJ, Selvin E, Thompson SG, Danesh J (2014) Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA 311:1225–1233. (PMID: 10.1001/jama.2014.1873) ; Lindstrom J, Tuomilehto J (2003) The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26:725–731. (PMID: 10.2337/diacare.26.3.725) ; Shahim B, Gyberg V, De Bacquer D, Kotseva K, De Backer G, Schnell O, Tuomilehto J, Wood D, Rydén L (2018) Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovasc Diabetol 17:21. (PMID: 10.1186/s12933-018-0665-4) ; Mavrogianni C, Lambrinou CP, Androutsos O, Lindström J, Kivelä J, Cardon G, Huys N, Tsochev K, Iotova V, Chakarova N, Rurik I, Moreno LA, Liatis S, Makrilakis K, Manios Y, Feel4Diabetes-study group (2019) Evaluation of the Finnish Diabetes Risk Score as a screening tool for undiagnosed type 2 diabetes and dysglycaemia among early middle-aged adults in a large-scale European cohort. The Feel4Diabetes-study. Diabetes Res Clin Pract 150:99–110. (PMID: 10.1016/j.diabres.2019.02.017) ; Pagano E, De Rosa M, Rossi E, Cinconze E, Marchesini G, Miccoli R, Vaccaro O, Bonora E, Bruno G (2016) The relative burden of diabetes complications on healthcare costs: the population-based CINECA-SID ARNO diabetes observatory. Nutr Metab Cardiovasc Dis 26:944–950. (PMID: 10.1016/j.numecd.2016.05.002) ; Peter P, Lipska KJ (2016) The rising cost of diabetes care in USA. Lancet Diabetes Endocrinol 4:479–480. (PMID: 10.1016/S2213-8587(15)00519-7) ; Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, Bärnighausen T, Davies J, Vollmer S (2018) Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care 41:963–970. (PMID: 10.2337/dc17-1962) ; Squires E, Duber H, Campbell M, Cao J, Chapin A, Horst C, Li Z, Matyasz T, Reynolds A, Hirsch IB, Dieleman JL (2018) Health care spending on diabetes in the U.S., 1996–2013. Diabetes Care 41:1423–1431. (PMID: 10.2337/dc17-1376) ; Ritchie GE, Kengne AP, Joshi R, Chow C, Neal B, Patel A, Zoungas S (2011) Comparison of near-patient capillary glucose measurement and a risk assessment questionnaire in screening for type 2 diabetes in a high-risk population in rural India. Diabetes Care 34:44–49. (PMID: 10.2337/dc10-1270) ; Bumrerraj S, Kaczorowski J, Kessomboon P, Thinkhamrop B, Rattarasarn C (2012) Diagnostic performance of 2 h postprandial capillary and venous glucose as a screening test for abnormal glucose tolerance. Prim Care Diabetes 6:207–211. (PMID: 10.1016/j.pcd.2012.03.002) ; Zhang Y, Sun J, Pang Z, Gao W, Sintonen H, Kapur A, Qiao Q (2013) Evaluation of two screening methods for undiagnosed diabetes in China: a cost-effectiveness study. Prim Care Diabetes 7:275–282. (PMID: 10.1016/j.pcd.2013.08.003) ; Toscano CM, Duncan BB, Mengue SS, Polanczyk CA, Nucci LB, Costa A, Fonseca CD, Schmidt MI, for the CNDDM Working Group (2008) Initial impact and cost of a natiowide population screening campaign for diabetes in Brazil: a follow-up study. BMC Health Service Res 8:189–199. (PMID: 10.1186/1472-6963-8-189) ; Bonaccorsi G, Guarducci S, Ruffoli E, Lorini C (2012) Diabetes screening in primary care: the PRE.DI.CO. study. Ann Ig 24:527–534. (PMID: 23234190) ; Gillet M, Brennan A, Watson P, Khunti K, Davies MJ, Mostafa S, Gray LJ (2015) The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study. NHS HTA 19. ; Gray LJ, Willis A, Webb D, Davies MJ, Khunti K (2018) Screening for diabetes and prediabetes. In: Bonora E, DeFronzo RA (eds) Diabetes epidemiology, genetics, pathogenesis, diagnosis and treatment. Springer International Publishing, Berlin, pp 369–400. (PMID: 10.1007/978-3-319-45015-5_12)
- Grant Information: RF-2011-02350193 Ministero della Salute
- Contributed Indexing: Keywords: Capillary blood glucose; Diabetes mellitus; Diabetes risk questionnaire; Prediabetes
- Substance Nomenclature: 0 (Biomarkers) ; 0 (Blood Glucose) ; 0 (Glycated Hemoglobin A) ; 0 (hemoglobin A1c protein, human)
- Entry Date(s): Date Created: 20200429 Date Completed: 20211004 Latest Revision: 20221207
- Update Code: 20240513
|
